...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC research notes >The effects of topical sodium cromoglicate on itch and flare in human skin induced by intradermal histamine: a randomised double-blind vehicle controlled intra-subject design trial
【24h】

The effects of topical sodium cromoglicate on itch and flare in human skin induced by intradermal histamine: a randomised double-blind vehicle controlled intra-subject design trial

机译：局部碳酸钠在皮内组胺诱导人体皮肤中的瘙痒和闪光的影响：随机双盲车控制内部主题设计试验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Itch is a prominent feature of many skin diseases, particularly atopic dermatitis and cutaneous mastocytosis. Sodium cromoglicate (SCG), a chromone developed for the treatment of allergic disease has been shown to reduce the severity of itch when applied topically to subjects with atopic dermatitis. The aim of this study was to investigate whether topical sodium cromoglicate can reduce the severity of itch induced by intradermal histamine. Methods SCG was introduced into the skin of healthy volunteers both by iontophoresis and by topical application using a new 4% cutaneous emulsion (Altoderm?). The skin was then challenged with intradermal histamine. Measurements were made of severity of itch, size of wheal and flare and change in blood flux Results SCG significantly reduced the severity of itch ( P = 0.0045) and flare ( P = 0.0143) when delivered by iontophoresis. SCG 4% cutaneous emulsion significantly reduced severity of itch ( P = 0.024) and flare ( P = 0.015) in atopic subjects. Trend analysis showed increasing effect on itch with increased concentrations of SCG, which was significant ( P = 0.046). There were no effects on wheal or blood flux. Conclusions Topically applied SCG, administered in a new cutaneous emulsion base, significantly reduced the itch and flare caused by intradermal histamine. The effect was greatest in atopic subjects and increased with the concentration of SCG in the emulsion. Trial registration ISRCTN35671014
机译：背景技术瘙痒是许多皮肤病，特别是特应性皮炎和皮肤吞咽症的突出特征。已显示用于治疗过敏性疾病的碳酸钠（SCG），用于治疗过敏性疾病的发球菌，以减少局部与特应性皮炎的受试者施用时的瘙痒的严重程度。本研究的目的是调查局部碳酸钠是否可以减少皮内组胺诱导的瘙痒的严重程度。方法通过离子电渗疗法和使用新的4％皮肤乳液（AltoDerm？）通过离子渗透性和局部应用引入健康志愿者的皮肤。然后用皮内组胺攻击皮肤。测量是由瘙痒的严重程度，脉冲和眩光的大小和血液通量的变化结果SCG在通过离子电渗疗法递送时显着降低了瘙痒的严重程度（P = 0.0045）和眩光（P = 0.0143）。 SCG 4％皮肤乳液显着降低了ATOPIC受试者中的瘙痒（P = 0.024）的严重程度（P = 0.024）并耀斑（P = 0.015）。趋势分析显示对瘙痒浓度增加的速度越来越大，SCG浓度显着（P = 0.046）。对冲或血液通量没有影响。结论局部施用的SCG，在新的皮肤乳液基础上施用，显着降低了皮内组胺引起的瘙痒和火炬。特应性受试者的效果最大，并且随着乳液中的SCG浓度而增加。试验登记ISRCTN35671014

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号